URGOSTART PLUS PAD 10X10cm (Piece)
UrgoStart Plus Pad is composed of a unique TLC-NOSF Healing Matrix (NOSF* impregnated in a TLC healing matrix), which has been shown to reduce excess Matrix Metalloproteinases (MMPs). In addition, UrgoStart Plus Pad unique poly-absorbent fibres come into direct contact with the wound to absorb and retain exudate. Thanks to their high affinity to slough, the fibres bind, trap and retain exudate, slough and debris present in the wound, keeping it clean throughout healing.
NICE 2019 medical technology guidance (MTG42) states that evidence supports the case for adopting UrgoStart dressings to treat diabetic foot ulcers and venous leg ulcers.
UrgoStart Plus is indicated for all stages (from the desloughing stage to complete healing) of exuding wounds including leg ulcers, diabetic foot ulcers, pressure ulcers, and long-standing acute wounds.
- With its unique TLC-NOSF* Healing Matrix (NOSF* impregnated in a TLC healing matrix) UrgoStart Plus is the only local treatment proven to reduce healing time and close wounds sooner
- The sooner the UrgoStart treatment range is initiated, the more effective it is.
- UrgoStart Plus range acts from Day 1 to complete healing, whatever the wound healing phase
- The UrgoStart Treatment range’s efficacy in healing significantly sooner has been demonstrated in the highest level of clinical studies (double-blind, randomised controlled trials) and through observational studies.
- Thanks to the TLC Technology, UrgoStart Plus maintains a moist wound healing environment and allows pain-free & atraumatic removals.
INSTRUCTION for Use
1.Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. Wound Rep Reg. 2012; 20: 4, 500-511.
2.Edmonds M, Lazaro-Martinez JL, Alfayate-Garcia JM, Martinin J, Petit JM, Rayman G, Lovmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3)186-196.
3.Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012;20:4, 500-511
4.Munter KC, Meaume S, Augustin M, Senet P, Kerijuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound care. 2017 Feb; 26 (sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3):153
5.Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014. July 2013.